1 January 2025 – 30 June 2025 (unaudited)
Attributable to shareholders of PolyPeptide Group AG:
|
|
|
|
|
|
|
|
|
|
kEUR |
Share capital |
Share premium |
Translation reserve |
Treasury shares |
Other capital reserves |
Retained earnings |
Total |
|
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2025 |
302 |
203,129 |
21,309 |
-8,398 |
425 |
140,477 |
357,244 |
|
|
|
|
|
|
|
|
|
|
Result for the period |
|
|
|
|
|
-26,539 |
-26,539 |
|
Remeasurement gain / (loss) on defined benefit plans, net of tax |
|
|
|
|
|
2,240 |
2,240 |
|
Currency exchange differences |
|
|
-2,437 |
|
|
|
-2,437 |
|
Total comprehensive income |
– |
– |
-2,437 |
– |
– |
-24,299 |
-26,736 |
|
|
|
|
|
|
|
|
|
|
Purchase of own shares |
|
|
|
-484 |
|
|
-484 |
|
Share-based payment |
|
|
|
|
961 |
|
961 |
|
Transfer of own shares |
|
|
|
1,429 |
-1,429 |
|
– |
|
Total transactions with owners |
– |
– |
– |
945 |
-468 |
– |
477 |
|
Balance as at 30 June 2025 |
302 |
203,129 |
18,872 |
-7,453 |
-43 |
116,178 |
330,985 |
1 January 2024 – 30 June 2024 (unaudited)
Attributable to shareholders of PolyPeptide Group AG:
|
|
|
|
|
|
|
|
|
|
kEUR |
Share capital |
Share premium |
Translation reserve |
Treasury shares |
Other capital reserves |
Retained earnings |
Total |
|
|
|
|
|
|
|
|
|
|
Balance as at 1 January 2024 |
302 |
203,129 |
21,832 |
-10,393 |
1,217 |
165,139 |
381,226 |
|
|
|
|
|
|
|
|
|
|
Result for the period |
|
|
|
|
|
-11,386 |
-11,386 |
|
Remeasurement gain / (loss) on defined benefit plans, net of tax |
|
|
|
|
|
-1,964 |
-1,964 |
|
Currency exchange differences |
|
|
-8,709 |
|
|
|
-8,709 |
|
Total comprehensive income |
– |
– |
-8,709 |
– |
– |
-13,350 |
-22,059 |
|
|
|
|
|
|
|
|
|
|
Share-based payment |
|
|
|
|
750 |
|
750 |
|
Transfer of own shares |
|
|
|
1,028 |
-1,028 |
|
– |
|
Total transactions with owners |
– |
– |
– |
1,028 |
-278 |
– |
750 |
|
Balance as at 30 June 2024 |
302 |
203,129 |
13,123 |
-9,365 |
939 |
151,789 |
359,917 |